{
    "clinical_study": {
        "@rank": "159601", 
        "arm_group": [
            {
                "arm_group_label": "TD-1211 IV [C14]", 
                "arm_group_type": "Experimental", 
                "description": "TD-1211 IV [C14]"
            }, 
            {
                "arm_group_label": "TD-1211 PO [C14]", 
                "arm_group_type": "Experimental", 
                "description": "TD-1211 PO [C14]"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine TD-1211 is processed by the body."
        }, 
        "brief_title": "TD-1211 IV/Oral Mass Balance Study", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "OIC", 
        "detailed_description": {
            "textblock": "This study will provide information regarding the metabolic pathway of TD 1211, the need for\n      evaluation of potential drug-drug interactions, the need for studies in special populations\n      and the absolute oral bioavailability of TD-1211.  The administration of radiolabeled drug\n      is necessary to fully characterize the rates and routes of elimination of TD 1211, providing\n      further quantitative information on the disposition of TD 1211.  The results from this study\n      will allow a more comprehensive comparison between animal and human routes of elimination\n      and metabolic profiles of TD 1211."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy, nonsmoking male, 18 to 50 years old, inclusive.\n\n          2. Agrees to use a highly effective method of birth control.\n\n          3. Body mass index (BMI) 19 to 30 kg/m2, inclusive, and weighs at least 55 kg.\n\n          4. Willing and able to give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Evidence or history of clinically significant allergic (except for untreated,\n             asymptomatic, seasonal allergies at time of dosing), hematological, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological\n             disease.\n\n          2. Hemoglobin <14.1 g/dL or hematocrit < 40.6% at Screening.\n\n          3. History of hypersensitivity to drugs, or a history of or any current clinically\n             significant hypersensitivities.\n\n          4. Any condition possibly affecting drug absorption (e.g., previous surgery on the\n             gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall\n             bladder, or pancreas]).\n\n          5. Participated in another clinical trial of an investigational drug (or medical device)\n             within 60 days (or 5 half-lives of the investigational drug, whichever is longer)\n             prior to Screening, or is currently participating in another trial of an\n             investigational drug (or medical device)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702194", 
            "org_study_id": "0087"
        }, 
        "intervention": [
            {
                "arm_group_label": "TD-1211 IV [C14]", 
                "intervention_name": "TD-1211 IV [C14]", 
                "intervention_type": "Drug", 
                "other_name": "TD-1211"
            }, 
            {
                "arm_group_label": "TD-1211 PO [C14]", 
                "intervention_name": "TD-1211 PO [C14]", 
                "intervention_type": "Drug", 
                "other_name": "TD-1211"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "OIC", 
            "Opioid Induced Constipation", 
            "Constipation"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin"
                }, 
                "name": "Covance"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Dose, Fixed-Sequence, Two-Period, Two\u2212Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD\u22121211 Following an Intravenous Infusion and an Oral Dose of [14C]TD\u22121211 in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "0 to 168 hours postdose"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 168 hours postdose"
            }, 
            {
                "measure": "Time to peak plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 168 hours postdose"
            }, 
            {
                "measure": "Half-life (T 1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 to 168 hours postdose"
            }, 
            {
                "measure": "Percent total recovery of radioactivity in blood, urine, and feces", 
                "safety_issue": "No", 
                "time_frame": "0 to 312 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702194"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to 14 days"
        }, 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}